<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966277</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0487</org_study_id>
    <secondary_id>NCI-2011-01773</secondary_id>
    <nct_id>NCT00966277</nct_id>
  </id_info>
  <brief_title>Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients</brief_title>
  <official_title>Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE
      occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who
      are going to receive chemotherapy. Some patients will receive dalteparin and some will
      receive no study drug.

      The safety of dalteparin will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug:

      Dalteparin is designed to thin the blood and block blood from clotting. This may lower the
      risk of VTE.

      Study Groups:

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the flip of a coin) into 1 of 2 groups. There is an equal chance of being assigned to
      either group.

      Group 1 will receive dalteparin.

      Group 2 will not receive a study drug.

      During this study, all study participants will be routinely checked for VTE by ultrasounds
      and CT scans.

      You may also receive standard therapies for preventing VTE. This may include blood-thinning
      drugs while you are in the hospital, getting up and moving around at least 5 times per day,
      and/or wearing special stockings or boot-like devices designed to put pressure on the feet.

      Genetic Research Testing:

      Before starting your therapy (at baseline), blood (about 1 teaspoon) will be drawn and stored
      for genetic testing. Researchers want to use DNA (the genetic material in cells) to look for
      markers that may be related to having a high risk for developing blood clots. The samples
      will be processed and stored at MD Anderson. Once this study ends, the DNA will be tested
      further in Dr. Futreal's laboratory and/or may be shipped outside to Illumina Sequencing
      Services (San Diego, CA) for genetic research. The samples will be deidentified before
      shipping.

      Before your samples are sent to the outside laboratory for banking, your name and any
      personal identifying information will be coded to protect your privacy. The outside
      researchers will not have access to the codes that link the samples to your identity.

      Study Drug Administration:

      If you are in Group 1, you will receive dalteparin by injection under your skin, once a day
      for 16 weeks. You and/or your caregiver will be taught how to perform injections.

      Study Visits:

      At every study visit, the following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs (blood
           pressure, heart rate, temperature and breathing rate).

        -  Your medical history will be recorded.

      About every 2 weeks after chemotherapy starts until Week 16, blood (about 2 teaspoons) will
      be drawn for routine tests. This test may be repeated more often if the doctor decides it is
      needed.

      Before each new cycle of chemotherapy during Weeks 1-16, blood (about 2 teaspoons) will be
      drawn for routine tests to check the function of your liver and kidneys.

      At Weeks 8 and 16 (+/- 7 days), the following procedures will be performed:

        -  You will have an ultrasound of your legs to check for blood clots.

        -  If the doctor decides it is needed, you will have CT scans to check the status of the
           cancer. Researchers will also check your chest CT scans to look for blood clots in the
           lungs.

      Length of Study Participation:

      You may remain on study for up to 16 weeks. You will be taken off study early if blood clots
      occur or you experience intolerable side effects.

      Follow-Up Phone Calls:

      This study has a 3-year follow-up period. In Year 1, you will receive a follow-up phone call
      from the study staff in the first month and then at Months 3, 6, 9, and 12. In Years 2 and 3,
      you will be called every 6 months.

      The study staff will ask about your overall health. In the first phone call, you will also be
      asked about any side effects that may have occurred.

      This is an investigational study. Dalteparin is commercially available and FDA approved for
      use in preventing VTE that may occur for other reasons. Those reasons include abdominal
      surgery; surgery for a hip fracture, hip replacement, or knee replacement; and illnesses
      causing patients to be unable to move around.

      Dalteparin is also commercially available and FDA approved to treat VTE in cancer patients.
      However, it is investigational to use dalteparin to prevent VTE in cancer patients receiving
      chemotherapy.

      Up to 87 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Venous Thromboembolic Events (VTE)</measure>
    <time_frame>16 weeks of treatment</time_frame>
    <description>Venous thromboembolism (VTE) defined by both symptomatic and asymptomatic VTE which includes deep venous thrombosis (DVT) and pulmonary embolism (PE) through clinical assessments and radiologic studies. All patients undergo bilateral lower extremity ultrasound every 2 months while on study (total of 3 exams including pre-randomization). VTE requires imaging documentation to evaluate use of prophylactic anticoagulation in reducing the occurrence of VTE in a patient population with a known high risk of VTE.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Group 1: Dalteparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>5000 units subcutaneous, by injection under the skin, daily for 16 weeks</description>
    <arm_group_label>Group 1: Dalteparin</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with the diagnosis of advanced stage (unresectable or metastatic)
             adenocarinoma of the pancreas. Patients with borderline resectable will also be
             eligible if they are starting chemotherapy and/or chemo/radiation therapy (RT) prior
             to attempting resection.

          2. Patients must be planning to initiate systemic chemotherapy within 2 weeks.
             Chemotherapy that is being given concurrently with radiation is allowed.

          3. Age &gt;/= 18 years old

          4. Adequate renal function defined as a calculated creatinine clearance of &gt; 50 mL/min
             (as reported by the MDACC laboratory using MDRD method or using Cockroft and Gault
             formula).

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          6. Negative urine or serum pregnancy test in women with childbearing potential, within
             one week prior to initiation of treatment.

          7. Patients must sign an Informed Consent.

          8. Patient must agree to transfusion of blood products, when indicated.

          9. Ability to administer subcutaneous injections of the study drug by the patient and/or
             care giver.

        Exclusion Criteria:

          1. Patients with evidence of venous thrombosis on the initial lower extremity screening
             ultrasound or incidental VTE of other sites (e.g. PE, Abdominal/pelvic vein
             thrombosis, etc.).

          2. Patients already taking prophylactic or full dose anticoagulation (eg. heparin,
             low-molecular weight heparin, fondaparinux, or coumadin).

          3. Patients with currently active bleeding.

          4. The presence of a condition with a high risk for bleeding, including but not limited
             to active peptic ulcer, recent neurosurgery, or cirrhosis with esophageal varices.

          5. Patients with known brain metastases.

          6. Patients with a known bleeding diathesis.

          7. Patients with a platelet count &lt; 50,000.

          8. Patients with known hypersensitivity to dalteparin.

          9. Patients who regularly use medications known to increase the risk of bleeding such as
             &gt;/= 325 mg of aspirin daily, or daily clopidogrel, or daily non-steroidal
             antiinflammatory medications (eg., ibuprofen, naproxen).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>October 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Primary venous thromboembolism</keyword>
  <keyword>VTE</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Deep venous thrombosis</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Dalteparin</keyword>
  <keyword>Fragmin</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: April 06, 2010 to August 23, 2012. All recruitment done at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 87 participants enrolled on the study, only 75 were randomized. Twelve enrolling participants were screen failures or withdrew before randomization thus were excluded before assignments to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Dalteparin</title>
          <description>Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Control</title>
          <description>No Dalteparin study drug (primary prophylaxis).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34">Four participants did not receive study treatment, see 'Reasons Not Completed.'</participants>
                <participants group_id="P2" count="33">Four participants did not receive study treatment, see 'Reasons Not Completed.'</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Plan Changed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Dalteparin</title>
          <description>Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Control</title>
          <description>No Dalteparin study drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="36" upper_limit="75"/>
                    <measurement group_id="B2" value="64" lower_limit="38" upper_limit="77"/>
                    <measurement group_id="B3" value="61.5" lower_limit="36" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causacian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Unreported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Venous Thromboembolic Events (VTE)</title>
        <description>Venous thromboembolism (VTE) defined by both symptomatic and asymptomatic VTE which includes deep venous thrombosis (DVT) and pulmonary embolism (PE) through clinical assessments and radiologic studies. All patients undergo bilateral lower extremity ultrasound every 2 months while on study (total of 3 exams including pre-randomization). VTE requires imaging documentation to evaluate use of prophylactic anticoagulation in reducing the occurrence of VTE in a patient population with a known high risk of VTE.</description>
        <time_frame>16 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Dalteparin</title>
            <description>Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Control</title>
            <description>No Dalteparin study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Venous Thromboembolic Events (VTE)</title>
          <description>Venous thromboembolism (VTE) defined by both symptomatic and asymptomatic VTE which includes deep venous thrombosis (DVT) and pulmonary embolism (PE) through clinical assessments and radiologic studies. All patients undergo bilateral lower extremity ultrasound every 2 months while on study (total of 3 exams including pre-randomization). VTE requires imaging documentation to evaluate use of prophylactic anticoagulation in reducing the occurrence of VTE in a patient population with a known high risk of VTE.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Follow-up/observation for all adverse events will be through Day 28 following the last dose of study drug or until resolution of any toxicity related to the study drug at the end of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Dalteparin</title>
          <description>Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Control</title>
          <description>No Dalteparin study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual (Other)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising/minor bleeding</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bruising/Bleeding</sub_title>
                <description>Grade 2/3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pulmonary (Other)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin (Other)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan-Raj, MD/Professor, Sarcoma Medical Oncology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

